162 related articles for article (PubMed ID: 38408970)
1. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study.
Kameda S; Maeda A; Maeda S; Inoue Y; Takahashi K; Kageyama A; Doi K; Fujii T
BMC Nephrol; 2024 Feb; 25(1):69. PubMed ID: 38408970
[TBL] [Abstract][Full Text] [Related]
2. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.
Kameda S; Fujii T; Ikeda J; Kageyama A; Takagi T; Miyayama N; Asano K; Endo A; Uezono S
BMC Nephrol; 2023 Jan; 24(1):12. PubMed ID: 36642717
[TBL] [Abstract][Full Text] [Related]
3. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
Miyaji MJ; Ide K; Takashima K; Maeno M; Krallman KA; Lazear D; Goldstein SL
Pediatr Nephrol; 2022 Nov; 37(11):2733-2742. PubMed ID: 35348901
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study.
Liu D; Zhao J; Xia H; Dong S; Yan S; Zhuang Y; Chen Y; Peng H
Eur J Med Res; 2024 Jan; 29(1):72. PubMed ID: 38245802
[TBL] [Abstract][Full Text] [Related]
5. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
Choi JY; Kang YJ; Jang HM; Jung HY; Cho JH; Park SH; Kim YL; Kim CD
Medicine (Baltimore); 2015 Dec; 94(52):e2392. PubMed ID: 26717390
[TBL] [Abstract][Full Text] [Related]
6. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Zarbock A; Küllmar M; Kindgen-Milles D; Wempe C; Gerss J; Brandenburger T; Dimski T; Tyczynski B; Jahn M; Mülling N; Mehrländer M; Rosenberger P; Marx G; Simon TP; Jaschinski U; Deetjen P; Putensen C; Schewe JC; Kluge S; Jarczak D; Slowinski T; Bodenstein M; Meybohm P; Wirtz S; Moerer O; Kortgen A; Simon P; Bagshaw SM; Kellum JA; Meersch M;
JAMA; 2020 Oct; 324(16):1629-1639. PubMed ID: 33095849
[TBL] [Abstract][Full Text] [Related]
7. Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Tsujimoto Y; Miki S; Shimada H; Tsujimoto H; Yasuda H; Kataoka Y; Fujii T
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013330. PubMed ID: 34519356
[TBL] [Abstract][Full Text] [Related]
8. Dialysis circuit clotting in critically ill patients with COVID-19 infection.
Khoo BZE; Lim RS; See YP; Yeo SC
BMC Nephrol; 2021 Apr; 22(1):141. PubMed ID: 33879086
[TBL] [Abstract][Full Text] [Related]
9. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
Baek NN; Jang HR; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
Ren Fail; 2012; 34(3):279-85. PubMed ID: 22251267
[TBL] [Abstract][Full Text] [Related]
10. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
Miyatake Y; Makino S; Kubota K; Egi M; Mizobuchi S
Kobe J Med Sci; 2017 Aug; 63(1):E30-E36. PubMed ID: 29434171
[TBL] [Abstract][Full Text] [Related]
11. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
[TBL] [Abstract][Full Text] [Related]
12. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
Lee YK; Lee HW; Choi KH; Kim BS
PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
[TBL] [Abstract][Full Text] [Related]
13. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study.
Rhee H; Berenger B; Mehta RL; Macedo E
Am J Kidney Dis; 2021 Oct; 78(4):550-559.e1. PubMed ID: 33798636
[TBL] [Abstract][Full Text] [Related]
14. Real-life effects, complications, and outcomes in 39 critically ill neonates receiving continuous kidney replacement therapy.
Xu J; Fang L; Chen J; Chen X; Yang H; Zhang W; Wu L; Chen D
Pediatr Nephrol; 2023 Sep; 38(9):3145-3152. PubMed ID: 36988692
[TBL] [Abstract][Full Text] [Related]
15. The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety.
Kim T; Kim DE; Jo EM; Lee Y; Kim DW; Kim HJ; Seong EY; Song SH; Rhee H
Kidney Res Clin Pract; 2024 Jun; ():. PubMed ID: 38934038
[TBL] [Abstract][Full Text] [Related]
16. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic instability during connection to continuous kidney replacement therapy in critically ill pediatric patients.
Thadani S; Fogarty T; Mottes T; Price JF; Srivaths P; Bell C; Akcan-Arikan A
Pediatr Nephrol; 2022 Sep; 37(9):2167-2177. PubMed ID: 35118547
[TBL] [Abstract][Full Text] [Related]
18. Association of continuous kidney replacement therapy timing and mortality in critically ill children.
Banigan MA; Keim G; Traynor D; Yehya N; Lindell RB; Fitzgerald JC
Pediatr Nephrol; 2024 Jul; 39(7):2217-2226. PubMed ID: 38396090
[TBL] [Abstract][Full Text] [Related]
19. Association of anticoagulation use during continuous kidney replacement therapy and 90-day outcomes: A multicentre study.
Lau YH; Li AY; Lim SL; Woo KL; Ramanathan K; Chua HR; Akalya K; Tan AY; Phua J; Tan JJ; Puah SH; Chia YW; Loh SC; Ahmed Khan F; Chatterjee S; Kaushik M; See KC;
Ann Acad Med Singap; 2023 Aug; 52(8):390-397. PubMed ID: 38920170
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Continuous Kidney Replacement Therapy and Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Cohort Study.
Okamoto K; Fukushima H; Kawaguchi M; Tsuruya K
Am J Kidney Dis; 2024 Mar; ():. PubMed ID: 38490319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
